In the news *AMSTERDAM, 26. ledna 2024 / PRNewswire/ –*(C-Path) has appointed Klause Romera, M.D., M.S., FCP, as its new Chief Executive Officer and promoted Cécile Ollivier, M.S., as the Vice President of Global Affairs in Europe.
Mr. Romero has been with C-Path for more than 16 years. In the past, he has held key positions, including the Director of Science and Executive Director of Clinical Pharmacology and Quantitative Medicine Program. He played a crucial role in establishing and leading the quantitative medicine program. This only highlights his remarkable contributions to C-Path’s core activities in drug development.
M. Wainwright Fishburn, Jr., Chairman of C-Path’s Board of Directors, said that “Dr. Romero’s exceptional expertise and leadership have been instrumental in assisting us in developing and implementing revolutionary scientific and regulatory approaches. His strategic vision perfectly aligns with C-Path’s goals of accelerating the development of new therapeutic treatments. We are confident that he will lead our organization to expand its global reach and produce entirely novel innovations to the next level.”
Talking about his new role, Romero said, “Assuming the role of CEO at C-Path is a great honor for me. It also comes with great responsibility. My goal is to continue the established tradition of delivering cutting-edge products and services and developing innovations that are unique to C-Path, thus changing drug development processes in favor of those who need them.” He added, “This commitment is deeply rooted in my early days at C-Path, where I was inspired by the visionary leadership of its founder, Dr. Raymond Woosley. We will continue to work together in our mission to revolutionize the drug development paradigm for those who need them.”
For more information on Dr. Romero’s appointment, please visit the official link.
Cécile Ollivier has been a key figure at C-Path since April 2021, when she joined as the Executive Director. In her new role, she will oversee global strategic initiatives focusing on strengthening international cooperation and innovating approaches for solving complex problems in drug development.
“We are excited to announce Cécile Ollivier’s appointment to Vice President of Global Affairs,” said Dr. Tomas Salmonson, Ph.D., M.S. “Cécile has been an invaluable asset to our operations in Europe and with her extensive experience in global drug development and regulatory sciences, she is an ideal candidate for this even more critical position. Her leadership will be instrumental in our continued efforts to accelerate drug development worldwide.”
Ollivier has more than 16 years of experience in the healthcare sector and has significantly contributed to drug development for children and the treatment of rare diseases. She has been internationally recognized for her efforts, including as an expert at the International Conference of Harmonization (ICH) and leading the global pediatric extrapolation strategy. Before joining C-Path, Ollivier worked at the European Medicines Agency (EMA) and in the healthcare technology industry, focusing on the development of digital devices for clinical studies.
Speaking about her new role, Ollivier said, “It is a great honor to take on this new role. The opportunity to make a significant impact in the worldwide healthcare outcomes and to support drug development innovations aligns perfectly with my own goals and professional experiences. I look forward to working with our talented team and partners worldwide to achieve a significant influence on the lives of individuals and families affected by diseases whose needs are currently unmet.”
For more information on Cécile Ollivier’s promotion, please visit the official link.
About Critical Path Institute
Critical Path Institute (C-Path) is an independent non-profit organization founded in 2005 as a public-private partnership in response to the Critical Path Initiative of the FDA. C-Path aims to promote collaboration that contributes to better therapeutic options for patients worldwide. The organization, a globally recognized leader in accelerating drug development, has formed several international consortia, programs, and initiatives. Over 1,600 scientists and representatives from government and regulatory agencies, academia, patient advocacy organizations, disease foundations, and pharmaceutical and biotech companies are currently involved. C-Path employees work worldwide, with its global headquarters in Tucson, Arizona, and its European office in Amsterdam, the Netherlands. For more information, please visit c-path.org.
Contacts:
Roxan Triolo Olivas
C-Path
520.954.1634
Source link
